175 related articles for article (PubMed ID: 31933229)
1. Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?
Maliepaard M; Taams AC; Sung C; Poh J; Yu Y
Pharmaceut Med; 2019 Oct; 33(5):407-416. PubMed ID: 31933229
[TBL] [Abstract][Full Text] [Related]
2. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
Beers E; Egberts TC; Leufkens HG; Jansen PA
Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.
Weersink RA; Timmermans L; Monster-Simons MH; Mol PGM; Metselaar HJ; Borgsteede SD; Taxis K
Front Pharmacol; 2019; 10():1031. PubMed ID: 31607904
[No Abstract] [Full Text] [Related]
4. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
5. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
6. Sex as a variable in medicines assessment reports for licensing in the European Union. Can gender bias be excluded?
Laguna-Goya N; de Andres-Trelles F
Eur J Clin Pharmacol; 2014 May; 70(5):519-25. PubMed ID: 24515611
[TBL] [Abstract][Full Text] [Related]
7. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
8. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
9. Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency.
Maliepaard M; Faber YS; van Bussel MTJ
Pharmacol Res Perspect; 2023 Apr; 11(2):e01067. PubMed ID: 36846954
[TBL] [Abstract][Full Text] [Related]
10. Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.
Orellana García LP; Ehmann F; Hines PA; Ritzhaupt A; Brand A
Front Med (Lausanne); 2021; 8():753187. PubMed ID: 34790681
[No Abstract] [Full Text] [Related]
11. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
[TBL] [Abstract][Full Text] [Related]
12. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
Cornelius VR; Liu K; Peacock J; Sauzet O
BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
[TBL] [Abstract][Full Text] [Related]
13. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics.
Albassam A; Hughes DA
Eur J Clin Pharmacol; 2021 Feb; 77(2):251-260. PubMed ID: 32989529
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of the European guidance on clinical investigation of medicines in children.
't Jong GW; Stricker BH; Choonar I; van den Anker JN
Acta Paediatr; 2002; 91(11):1233-8. PubMed ID: 12463324
[TBL] [Abstract][Full Text] [Related]
15. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
[TBL] [Abstract][Full Text] [Related]
16. Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.
Berntgen M; Gourvil A; Pavlovic M; Goettsch W; Eichler HG; Kristensen FB
Value Health; 2014 Jul; 17(5):634-41. PubMed ID: 25128058
[TBL] [Abstract][Full Text] [Related]
17. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
18. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.
Sillo HB; Masota NE; Kisoma S; Rago L; Mgoyela V; Kaale EA
PLoS One; 2018; 13(5):e0197490. PubMed ID: 29787579
[TBL] [Abstract][Full Text] [Related]
19. The Quality and Reliability of Information in the Summaries of Product Characteristics.
Drelich E; Religioni U; Chung K; Kaźmierczak J; Blicharska E; Neumann-Podczaska A; Krysiński J; Merks P
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206371
[TBL] [Abstract][Full Text] [Related]
20. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
